Elanco
2001 West Main Street
P.O. Box 708
Greenfield
Indiana
46140
United States
Tel: 800-428-4441
Fax: 317-276-9434
About Elanco
At Elanco, we provide those who raise and care for animals with solutions that empower them to advance a vision of food and companionship enriching life. We understand the powerful role healthy animals play in making lives better. As pets increasingly become important parts of our families, so too does the need to help them live longer, healthier, higher-quality lives. As the global population grows, so too will the need to meet the demand for safe, affordable food for all. Since our start at Eli Lilly and Company in 1954, Elanco has been working to empower our customers—from veterinarians to food producers to all those concerned with animal health—to address these global challenges, and advance a vision of food and companionship enriching life. We strive to develop and deliver products safe for consumers, animals and the environment through innovation and a shared vision to enrich the life of people worldwide.
51 articles about Elanco
-
Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary
3/4/2024
Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary.
-
Elanco to Participate in Upcoming Investor Conferences
2/22/2024
Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
-
Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary
6/4/2021
Today, Elanco Animal Health Incorporated (NYSE: ELAN) named Marcela A. Kirberger as general counsel and corporate secretary. She joins the Elanco Executive Committee at the company’s Greenfield, Indiana-based headquarters on June 22.
-
Elanco Animal Health Reports First Quarter 2021 Results
5/7/2021
Exceeded first quarter 2021 guidance; Updating full year 2021 guidance, raising and tightening adjusted ranges Revenue in the first quarter was $1,242 million, comprised of $683 million from the legacy Elanco portfolio and $559 million from the legacy Bayer Animal Health portfolio.
-
Elanco to Participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference
11/19/2020
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:00 p.m. ET. A live audio webcast will be available on the “Events and Presentations” section of Elanco’s investor website . A replay will be available for approximately one year.
-
Elanco to Participate in Goldman Sachs 41st Annual Global Healthcare Conference
6/3/2020
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Goldman Sachs 41 st Annual Global Healthcare Conference Webcast on Wednesday, June 10, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:00 p.m. EDT. A live video webcast will be available on the “Events and Presentations” section of Elanco’s investor website at https://investor.elanco.com/investors/events-
-
ELAN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Elanco Animal Health Incorporated and Encourages Investors to Contact the Firm
5/22/2020
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Elanco securities between January 10, 2020 a
-
Elanco to Participate in the Bank of America Securities Health Care Conference
5/12/2020
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 1:00 p.m. EDT. A live audio webcast will be available on the “Events and Presentations” section of Elanco’s investor website at https://investor.elanco.com/investors/events-and-presenta
-
Elanco Signs Agreement with Merck Animal Health to Divest Worldwide Rights for Vecoxan®
2/19/2020
Elanco Animal Health Incorporated announced it signed an agreement with Merck Animal Health to divest worldwide rights for Vecoxan® for $55 million in an all-cash deal.
-
Elanco’s East Africa Growth Accelerator Delivers $8+ Million in Socio-Economic Value for Smallholder Farmers in East Africa, Progress Against Sustainable Development Goals
2/17/2020
Feb. 17, 2020 13:35 UTC GREENFIELD, Ind.--( BUSINESS WIRE )-- Elanco Animal Health Inc. (NYSE: ELAN) today announced that its shared value East Africa Growth Accelerator (EAGA) initiative has delivered a Social Return on Investment (SROI) of almost 250% for dairy and poultry smallholder farmers, their families and other stakeholders in the region. For every US$1 invested by Elanco and its partners in the EAGA initiative during its initial phase from June 2017 to December 2018, $2.
-
Elanco’s East Africa Growth Accelerator delivers $8+ million in socio-economic value for smallholder farmers in East Africa, progress against Sustainable Development Goals
2/17/2020
GREENFIELD, Ind., Feb. 17, 2020 (GLOBE NEWSWIRE) -- Elanco Animal Health Inc. (NYSE: ELAN) today announced that its shared value East Africa Growth Accelerator (EAGA) initiative has delivered a Social Return on Investment (SROI) of almost 250% for dairy and poultry smallholder farmers, their families and other stakeholders in the region. For every US$1 invested by Elanco and its partners in the EAGA initiative during its initial phase from June 2017 to December 2018, $2.48 of socio-economic va
-
Elanco Sells Victoria, PEI, Canada R&D Facility to The Center for Aquaculture Technologies Canada (CATC)
12/24/2019
Elanco Animal Health Incorporated has signed an agreement to sell its Victoria, Prince Edward Island aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI.
-
Elanco Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement
10/14/2019
Elanco Animal Health will announce its third-quarter 2019 financial results on Wednesday, November 6, 2019.
-
Elanco Advances Margin Expansion Journey with Business Restructuring
9/30/2019
Since its September 2018 initial public offering (IPO), Elanco Animal Health Inc. (NYSE: ELAN) has continued to evaluate its capabilities, structure and staffing to meet its goal of being an agile, standalone company, focused exclusively on animal health and delivering on its Innovation, Portfolio and Productivity (IPP) strategy.
-
Elanco to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
9/5/2019
Jeff Simmons, Elanco president and chief executive officer, will participate in a fireside chat at 8:45 a.m. Eastern Time.
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
-
Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health
7/16/2019
Aratana Reports Voting Results from 2019 Special Meeting of Stockholders
-
Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation
6/27/2019
Collaboration furthers Elanco’s commitment to antibiotic stewardship and offering alternatives to pork producers’ most difficult challenges
-
New Study Suggests Service Dogs Can Impact Psychosocial Health of Household
5/21/2019
Purdue Veterinary Medicine Researchers Document Benefits of Service Dogs for Recipients and Family Members
-
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.